Objectives: The aim of this study was to estimate the in vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during national surveillance in Belgian acute-care hospitals. Ceftaroline-resistant isolates were further investigated for their resistance mechanisms.
Introduction
Ceftaroline, the active metabolite of the pro-drug ceftaroline fosamil, is a cephalosporin with strong in vitro activity against MRSA. This antibiotic was approved in Europe in 2012 for the treatment of community-acquired bacterial pneumonia and skin or soft tissue infections. 1 The efficacy of ceftaroline against MRSA is explained by its increased affinity to PBP2a, the additional PBP protein encoded by the mecA gene acquired through the horizontal acquisition of the staphylococcal cassette chromosome mec (SCCmec). 2 Despite its recent approval, ceftaroline-resistant isolates have been identified worldwide. 2 -9 However in Belgium, ceftaroline-resistant isolates have not yet been identified. 9 Resistance is mainly mediated by amino acid (AA) substitutions in PBP2a, 3 -8 but ceftaroline-resistant strains with AA substitutions in PBP2 have also been described in the USA. 2 Besides clinical isolates, ceftaroline-passaged mutants, without AA changes in PBP2a, but with mutations in native pbp genes or in genes involved in b-lactam tolerance (acrB, pp2C, clpX, rho, gdpP), have been described. 10, 11 The aim of this study was to estimate the in vitro activity of ceftaroline against S. aureus isolates collected during nationwide surveillance conducted in Belgian hospitals. Isolates with reduced susceptibility to ceftaroline were characterized for the presence of mutations in genes encoding PBP2a, native PBP (PBP1, PBP2, PBP3, PBP4) and GdpP.
Methods

Bacteria collection
From October 2013 to March 2014, 155 laboratories of Belgian acutecare hospitals were invited to send to the National Reference 
PCR-based methods, molecular typing and antimicrobial resistance
The isolates were analysed by spa typing and PCR for detection of 16S-mecA-nuc and 16S-mecC genes. 12 MRSA (mecA or mecC positive) were further analysed for SCCmec typing. 12 MICs of oxacillin, cefoxitin and ceftaroline were determined by the broth microdilution method (Sensititre; Trek Diagnostic Systems, West Sussex, UK). MICs were interpreted according to the EUCAST clinical breakpoints. 13 Ceftarolineresistant isolates were further analysed by MLST. 14 
Sequence analysis
The mecA, pbp1, pbp2, pbp3, pbp4 and gdpP genes of isolates showing an MIC of ceftaroline .1 mg/L were amplified and sequenced using primers previously described or designed for this study (Table S1 , available as Supplementary data at JAC Online). Amplicons were obtained by using the PCR Master Mix Promega Benelux BV, and later purified with the illustra TM ExoStar TM 1-Step kit (GE Healthcare). Custom primers were designed to sequence each entire gene. Sequencing was performed using the Dye Terminator DNA sequencing kit V1.1 (Applied Biosystems) followed by a purification using the Performa DTR Ultra 96-well Plate kit (Edge Bio). Sequences were assembled and analysed using the BioNumerics 7.6 software (Applied Maths). The sequences obtained were compared with available sequences of reference strains from the NCBI database. 15 The MRSA strain N315 was used as the reference for the mecA gene, while the MSSA strains ATCC 25923, ATCC 9144, NCTC 8325 and MSSA476 were used as the references for the pbp1, pbp2, pbp3, pbp4 and gdpP genes. (Table 1) . These isolates showed diverse nucleotide missense mutations in pbp and gdpP genes responsible for AA substitutions (Table 1) . Three isolates had mutations in native pbp genes, and two of them also exhibited AA substitutions in PBP2a. The CC5 isolate did not present AA substitutions in pbp genes, but carried AA substitutions in GdpP, including one that does not allow the transcription of a complete Table 1 . Isolates were compared with reference strains with sequences available at the NCBI database. 15 The MRSA strain N315 was used as the reference for the mecA gene, while the MSSA strains ATCC 25923, ATCC 9144, NCTC 8325 and MSSA476 were used as the references for the pbp1, pbp2, pbp3, pbp4 and gdpP genes. AA substitutions found in the isolates that were also presented by the MSSA reference strains are omitted. AA substitutions in the transpeptidase domain of the PBPs are indicated in bold.
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Nucleotide change from adenine to thymine at position 958 generates a stop codon and reduces the size of the protein from 655 to 319 AAs.
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GdpP protein. The remaining AA substitution in GdpP (D105N) was also found in the CC5 reference strain N315.
Discussion
Ceftaroline has shown potent in vitro activity against contemporary MRSA and MSSA isolates collected in Belgium. Only 1.4% of MRSA isolates showed resistance to this antibiotic. As far as we know this is the first in vitro study on Belgian isolates that has detected ceftaroline-resistant S. aureus. Belgian isolates previously investigated by Karlowsky et al. 9 were ceftaroline susceptible with MICs ≤1 mg/L. The Belgian isolates from our study belonged to different lineages (CC5, CC22, CC8), CC5 2,6,8 and CC8-ST288/239 3, 5, 7, 8 being previously associated with ceftaroline resistance. CC22 isolates with an AA substitution (E239K) in PBP2a, but phenotypically ceftaroline susceptible, have recently been described in the UK. 17 Ceftaroline resistance has mainly been related to AA substitutions in PBP2a, but in our study only two isolates carried mutations in mecA that have also been detected in ceftaroline-susceptible strains. 4 -6,17 The CC22-ST3313 isolate and the CC8-ST239 isolate showed the AA substitution G246E in PBP2a, which has been described in strains from diverse lineages (CC5, CC8, CC45) with a ceftaroline MIC ≤1 mg/L. 4 -6 The PBP2a sequence of the CC8-ST239 isolate carried two AA substitutions (N146K, N204K) previously described in CC8-ST228/239 strains with reduced susceptibility to ceftaroline. 3, 5, 7, 8 However, these AA substitutions (N146K, N204K) have also recently been found in a susceptible CC8-ST241 isolate from the UK. 17 Besides, the four ceftaroline-resistant isolates carried mutations in native pbp or gdpP genes. As far as we know, only the study by Fernandez et al.
2 included ceftaroline-resistant clinical isolates with AA substitutions in PBP2, but not in PBP2a. Mutations in pbp genes, as well as in genes that may have a role in b-lactam tolerance (acrB, pp2C, clpX, rho, gdpP) have recently been described in ceftaroline-passaged mutants. 10, 11 Mutations in native pbp and gdpP genes have also been related to methicillin resistance in the absence of mec genes. 18, 19 However, the missense mutations in pbp and gdpP genes in ceftaroline-passaged mutants and mec-negative isolates were different from those detected in the ceftaroline-resistant isolates of our study. 10, 11, 18, 19 The research performed by Greninger et al. 11 supported that the pbp4 gene is strongly associated with resistance to fifth-generation cephalosporins such as ceftaroline. Previously, it has been shown that loss of PBP4 reduces b-lactam resistance in community-acquired MRSA isolates, because this PBP has a cooperative activity with PBP2 and PBP2a. 20 Regarding the non-pbp genes, it is noteworthy that the b-lactam tolerance provided by AA substitutions and/or loss of function of the phosphodiesterase GdpP has been related to increased pbp4-transcript levels. 21 These reports suggest that PBP4 has an important role in the ceftaroline resistance.
Conclusions
Ceftaroline resistance seems a complex phenomenon, in which isolates of different lineages can be implicated due to the accumulation of mutations in genes involved in b-lactam tolerance. Our data support that, besides mutations in mecA, secondary chromosomal mutations are likely to be involved in the ceftaroline resistance as previously suggested. 10, 11, 17 These data are worrisome, since non-mecA mechanisms can be selected in both MSSA and MRSA. Therefore, prudent use of fifth-generation cephalosporins is needed to avoid an increase in these new resistance mechanisms. Further studies are needed to understand this emerging non-mecA-mediated resistance phenomenon.
Nucleotide accession numbers
The mecA, pbp1, pbp2, pbp3, pbp4 and gdpP sequences generated in this study were deposited in GenBank (accession numbers KX139522 -KX139545).
